Danny Liaw | Senior Principal Scientist
Merck

Danny Liaw is a member of the Oncology Early Clinical Development organization at Merck. He has 15+ years industry experience in multiple therapeutic areas, starting at Bristol-Myers Squibb (BMS) where he was on the clinical development team for the oral factor Xa inhibitor, Eliquis, and led three registrational intent trials. Also at BMS, he co-led the design of a cardiovascular outcomes trial for the SGLT-2 inhibitor, Farxiga, before transitioning to BMS’s oncology group where he worked on the IDO1 inhibitor, linrodostat. After joining Merck in 2019, he worked on the Merck-Moderna collaboration for mRNA cancer therapies.
He received his MD and PhD from Columbia University, the latter in the laboratory of Ramon Parsons as a member of the team that made the discovery and early characterization of the PTEN tumor suppressor gene.